EPHX1
Basic information
Region (hg38): 1:225810124-225845563
Previous symbols: [ "EPHX" ]
Links
Phenotypes
GenCC
Source:
- familial hypercholanemia (Supportive), mode of inheritance: AR
- hereditary nonpolyposis colon cancer (Limited), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Hypercholanemia, familial | AR | Gastrointestinal | As in other forms of familial hypercholanemia, individuals may respond to medical treatment (eg, with ursodeoxycholic acid) | Gastrointestinal | 12878321; 15768832 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the EPHX1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 12 | 15 | ||||
missense | 23 | 30 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 27 | 27 | ||||
Total | 0 | 0 | 23 | 5 | 44 |
Variants in EPHX1
This is a list of pathogenic ClinVar variants found in the EPHX1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-225828680-G-A | Benign (Nov 11, 2018) | |||
1-225828696-G-A | Benign (Nov 11, 2018) | |||
1-225828763-G-A | not specified | Uncertain significance (Oct 26, 2022) | ||
1-225828790-C-T | not specified | Uncertain significance (Sep 26, 2022) | ||
1-225828866-A-G | not specified | Uncertain significance (Sep 12, 2023) | ||
1-225828874-C-T | Benign (Jul 06, 2018) | |||
1-225828932-G-A | Benign (Nov 10, 2018) | |||
1-225831546-CA-C | Benign (Jun 19, 2021) | |||
1-225831546-CAAAAAA-C | Benign (Jun 19, 2021) | |||
1-225831546-C-CA | Benign (Jun 20, 2021) | |||
1-225831554-AAAAAAG-A | Benign (Jun 18, 2021) | |||
1-225831555-AAAAAG-A | Benign (Jun 18, 2021) | |||
1-225831560-GAA-G | Benign (Jun 19, 2021) | |||
1-225831560-GAAAA-G | Benign (Jun 21, 2021) | |||
1-225831670-G-T | Benign (Nov 12, 2018) | |||
1-225831799-T-C | EPHX1-related disorder | Benign (Jul 16, 2019) | ||
1-225831807-G-A | Benign (Jul 10, 2018) | |||
1-225831827-G-A | not specified | Uncertain significance (Aug 08, 2022) | ||
1-225831841-C-G | not specified | Uncertain significance (Apr 04, 2024) | ||
1-225831898-T-C | Likely benign (Jun 18, 2018) | |||
1-225831932-T-C | EPOXIDE HYDROLASE 1 POLYMORPHISM • Cystic fibrosis | Benign (Nov 10, 2018) | ||
1-225831952-G-A | Benign (Nov 11, 2018) | |||
1-225832073-G-C | Benign (Nov 11, 2018) | |||
1-225838540-C-G | Benign (Nov 11, 2018) | |||
1-225838651-C-A | Benign (Dec 01, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
EPHX1 | protein_coding | protein_coding | ENST00000366837 | 8 | 35467 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.22e-9 | 0.520 | 125693 | 0 | 55 | 125748 | 0.000219 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.0563 | 256 | 253 | 1.01 | 0.0000153 | 2987 |
Missense in Polyphen | 75 | 88.261 | 0.84975 | 1053 | ||
Synonymous | -0.597 | 115 | 107 | 1.07 | 0.00000707 | 868 |
Loss of Function | 1.11 | 16 | 21.6 | 0.742 | 0.00000113 | 245 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000560 | 0.000560 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000272 | 0.000272 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000246 | 0.000246 |
Middle Eastern | 0.000272 | 0.000272 |
South Asian | 0.000196 | 0.000196 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Biotransformation enzyme that catalyzes the hydrolysis of arene and aliphatic epoxides to less reactive and more water soluble dihydrodiols by the trans addition of water (By similarity). May play a role in the metabolism of endogenous lipids such as epoxide-containing fatty acids (PubMed:22798687). {ECO:0000250|UniProtKB:P07687, ECO:0000269|PubMed:22798687}.;
- Disease
- DISEASE: Familial hypercholanemia (FHCA) [MIM:607748]: A disorder characterized by elevated serum bile acid concentrations, itching, and fat malabsorption. {ECO:0000269|PubMed:12878321}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Bile secretion - Homo sapiens (human);Metabolism of xenobiotics by cytochrome P450 - Homo sapiens (human);Chemical carcinogenesis - Homo sapiens (human);Carbamazepine Pathway, Pharmacokinetics;Warfarin Pathway, Pharmacodynamics;Phenytoin Pathway, Pharmacokinetics;Phenytoin (Antiarrhythmic) Action Pathway;Carbamazepine Metabolism Pathway;Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling;Benzene metabolism;Benzo(a)pyrene metabolism;Aflatoxin B1 metabolism;Metapathway biotransformation Phase I and II;Phase I - Functionalization of compounds;eicosanoid metabolism;Biological oxidations;Metabolism;Linoleate metabolism;Putative anti-Inflammatory metabolites formation from EPA;Xenobiotics metabolism;Arachidonic acid metabolism
(Consensus)
Recessive Scores
- pRec
- 0.665
Intolerance Scores
- loftool
- 0.843
- rvis_EVS
- 0.71
- rvis_percentile_EVS
- 85.76
Haploinsufficiency Scores
- pHI
- 0.135
- hipred
- N
- hipred_score
- 0.216
- ghis
- 0.394
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.226
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | High | High | High |
Primary Immunodeficiency | High | High | High |
Cancer | High | High | High |
Mouse Genome Informatics
- Gene name
- Ephx1
- Phenotype
- neoplasm; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- xenobiotic metabolic process;response to toxic substance;response to organic cyclic compound;aromatic compound catabolic process;epoxide metabolic process
- Cellular component
- endoplasmic reticulum membrane;integral component of membrane;organelle membrane
- Molecular function
- epoxide hydrolase activity;cis-stilbene-oxide hydrolase activity